Go Pro
NASDAQ:IXHL

Incannex Healthcare Q4 2026 Earnings Report

Incannex Healthcare logo
$3.59 -0.21 (-5.53%)
Closing price 09/17/2026 04:00 PM Eastern
Extended Trading
$3.56 -0.02 (-0.70%)
As of 04:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Incannex Healthcare EPS Results

Actual EPS
N/A
Consensus EPS
$0.13
Beat/Miss
N/A
One Year Ago EPS
N/A

Incannex Healthcare Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.20 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Incannex Healthcare Announcement Details

Quarter
Q4 2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Incannex Healthcare Earnings Headlines

My next big call (under $1)
17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of. But the world's largest bank is already building on it. It has a deflationary burn mechanism tied directly to institutional usage.tc pixel
Incannex Healthcare Inc.
See More Incannex Healthcare Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Incannex Healthcare? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Incannex Healthcare and other key companies, straight to your email.

About Incannex Healthcare

Incannex Healthcare (NASDAQ:IXHL) Limited (NASDAQ: IXHL) is a clinical-stage biotechnology company developing pharmaceutical products and therapies for conditions with significant unmet medical needs. The company’s research focuses on cannabinoid- and psychedelic-assisted treatments, with programs addressing sleep-disordered breathing, pain, inflammation, mental health and other complex disorders.

One of Incannex’s principal programs is IHL-42X, an investigational combination of dronabinol and acetazolamide being developed for obstructive sleep apnea. The company has also pursued cannabinoid-based candidates for inflammatory and fibrotic diseases, pain conditions and traumatic brain injury, as well as psychedelic-assisted therapies for psychiatric disorders such as generalized anxiety disorder. These products remain investigational and are subject to clinical and regulatory review.

Founded in Australia, Incannex has conducted research and clinical development activities in Australia and the United States. The company’s securities trade on the Nasdaq Capital Market under the symbol IXHL, and it has historically been led by Managing Director and Chief Executive Officer Joel Latham. Incannex’s development strategy is centered on advancing its drug candidates through clinical trials and, where appropriate, seeking regulatory approval and commercialization partnerships.

View Incannex Healthcare Profile